Spectrum Pharmaceuticals, Inc. (SPPI) Licenses Belinostat from TopoTarget A/S for $30 Million Upfront, Potential Payments of Up to $320 Million
2/2/2010 6:44:25 AM
More...
|
TopoTarget A/S Now Initiates Recruitment of Patients in Its First Pivotal Trial of Belinostat in Peripheral T-Cell Lymphoma (PTCL)
12/18/2008 11:46:23 AM
More...
|
Positive SPA Reply From the FDA for TopoTarget A/S's Pivotal Trial With Belinostat in PTCL Update on the Regulatory Strategy for Belinostat in PTCL
9/5/2008 10:53:28 AM
More...
|
CuraGen Corporation (CRGN) Sells 5 Million TopoTarget A/S Shares for Approximately $12 Million
5/23/2008 7:37:21 AM
More...
|
CuraGen Corporation (CRGN) Sells Ownership of Belinostat to TopoTarget A/S for Approximately $39 Million Upfront
4/22/2008 6:42:54 AM
More...
|
CuraGen Corporation (CRGN) and TopoTarget A/S Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
12/19/2007 8:05:05 AM
More...
|
CuraGen Corporation (CRGN) and TopoTarget A/S Report Belinostat Results Presented at American Society of Hematology and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
12/11/2007 7:33:49 AM
More...
|
CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
11/27/2007 10:09:26 AM
More...
|
CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
10/26/2007 7:57:19 AM
More...
|
CuraGen Corporation (CRGN) and TopoTarget A/S Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
8/28/2007 7:26:30 AM
More...
|
|